What’s New in the Pharmacological
Management of Prostate Cancer
A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive of the live session held at the 2010 Fall Managed Care Forum. If you participated in the live activity, you are not eligible for continuing education credits from this archive.

This activity is valid from July 18, 2011 to July 18, 2012
These presentations require Internet Explorer 5.0 or later, Netscape Navigator 7.0 or later, or Internet Explorer 5.2.2 for Mac.  To Download the latest version of Internet Explorer from the Microsoft web site, click here.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Dendreon Corporation
 
PLEASE CLICK HERE TO VIEW THE PRESENTATION

 PLEASE CLICK HERE FOR POST TEST AND EVALUATION

Instructions for CME/CEU: Read the article, answer the post test, complete the evaluation form, and hit submit. A score of 70% must be achieved on the post test to receive continuing education credits. You will have the option on the post test/evaluation page to submit your forms electronically or you can fax them to Katie Eads at 804-747-5316.

Description
Early detection and timely treatment of prostate cancer can greatly improve both survival rates and quality of life. With the advancement and complexity of different treatment options, clinicians are being challenged to quickly diagnose prostate cancer, it's corresponding stage, and provide the correct treatment options that are available to patients.

Treatments are evolving so quickly for prostate cancer patients, and it is becoming more and more difficult for clinicians, medical directors and nurses to keep up with the latest options that might be available for their patient populations. Continuing education about prostate cancer is key in keeping these healthcare professionals up to date on both agents that are available now, and those that will become available in the near future.

Upon Completion of this activity, participants will be able to:

  • Identify methods to use in population health management for Prostate Cancer

  • Describe new hormonal agents used in the setting of prostate cancer

  • Detail the role of novel chemotherapeutic agents in castration-resistant prostate cancer

  • Summarize the epidemiology of prostate cancer and evaluate tools for risk stratification and staging

  • Discuss the treatment options that are currently in the pipeline for use in the near future

  • Review NCCN Guidelines on the management of prostate cancer

Faculty: Nicholas J. Vogelzang, MD
Chair and Medical Director, Developmental Therapeutics Committee
US Oncology Research, Comprehensive Cancer Centers of Nevada
Professor of Medicine, University of Nevada School of Medicine, Las Vegas, NV

Disclosure:

 Dr. Vogelzang receives research support from NCI, ACS, Astra Zeneca, Abbott, Medarex, Fugisawa, Mannkind, Lilly, Novartis, Pfizer, and Cougar. He is on the speakers bureau/consultancies for Abbott, Aventis, Amgen, Merck EMD, BMS, GPC, Genta, Ortho, Astra Zeneca, MEC, MEI, Bayer, Lilly, Pfizer, GSK, Genentech, Celgene, and Veridex.
  Planning Committee:
 Bill Williams, MD has no real or perceived financial relationships to disclose.
 Katie Eads has no real or perceived financial relationships to disclose.
NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses (AAMCN) has been approved as a provider of continuing education by the Virginia Nurses Association (VNA). VNA is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will be awarded 1.0 contact hours.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.
   

This activity is supported by an educational grant from Dendreon Corporation
 

NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.